feed,title,long_url,short_url
Yahoo,Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes,https://finance.yahoo.com/news/empagliflozin-meets-primary-endpoint-reducing-120000437.html,https://j.mp/30sziXf
